Literature DB >> 21164019

Sclerostin and Dickkopf-1 in renal osteodystrophy.

Daniel Cejka1, Johann Herberth, Adam J Branscum, David W Fardo, Marie-Claude Monier-Faugere, Danielle Diarra, Martin Haas, Hartmut H Malluche.   

Abstract

BACKGROUND AND OBJECTIVES: The serum proteins sclerostin and Dickkopf-1 (Dkk-1) are soluble inhibitors of canonical wnt signaling and were recently identified as components of parathyroid hormone (PTH) signal transduction. This study investigated the associations between sclerostin and Dkk-1 with histomorphometric parameters of bone turnover, mineralization, and volume in stage 5 chronic kidney disease patients on dialysis (CKD-5D). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a cross-sectional study, 60 CKD-5D patients underwent bone biopsies followed by histomorphometry. Levels of sclerostin, Dkk-1, and intact PTH (iPTH) were determined in blood.
RESULTS: Serum levels of sclerostin and iPTH correlated negatively. In unadjusted analyses, sclerostin correlated negatively with histomorphometric parameters of turnover, osteoblastic number, and function. In adjusted analyses, sclerostin remained a strong predictor of parameters of bone turnover and osteoblast number. An observed correlation between sclerostin and cancellous bone volume was lost in regression analyses. Sclerostin was superior to iPTH for the positive prediction of high bone turnover and number of osteoblasts. In contrast, iPTH was superior to sclerostin for the negative prediction for high bone turnover and had similar predictive values than sclerostin for the number of osteoblasts. Serum levels of Dkk-1 did not correlate with iPTH or with any histomorphometric parameter.
CONCLUSIONS: Our data describe a promising role for serum measurements of sclerostin in addition to iPTH in the diagnosis of high bone turnover in CKD-5D patients, whereas measurements of Dkk-1 do not seem to be useful for this purpose.
© 2011 by the American Society of Nephrology

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21164019      PMCID: PMC3069382          DOI: 10.2215/CJN.06550810

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   10.614


  31 in total

1.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Authors:  David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

Review 2.  Influence of the parathyroid glands on bone metabolism.

Authors:  H H Malluche; N Koszewski; M C Monier-Faugere; J P Williams; H Mawad
Journal:  Eur J Clin Invest       Date:  2006-08       Impact factor: 4.686

3.  Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation.

Authors:  Jun Guo; Minlin Liu; Dehong Yang; Mary L Bouxsein; Hiroaki Saito; R J Sells Galvin; Stuart A Kuhstoss; Clare C Thomas; Ernestina Schipani; Roland Baron; F Richard Bringhurst; Henry M Kronenberg
Journal:  Cell Metab       Date:  2010-02-03       Impact factor: 27.287

4.  Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease.

Authors:  B Peter Sawaya; Rezkalla Butros; Shehzab Naqvi; Zhaopo Geng; Hanna Mawad; Robert Friedler; Paolo Fanti; Marie-Claude Monier-Faugere; Hartmut H Malluche
Journal:  Kidney Int       Date:  2003-08       Impact factor: 10.612

Review 5.  The role of Dickkopf-1 in bone development, homeostasis, and disease.

Authors:  Joseph J Pinzone; Brett M Hall; Nanda K Thudi; Martin Vonau; Ya-Wei Qiang; Thomas J Rosol; John D Shaughnessy
Journal:  Blood       Date:  2008-08-07       Impact factor: 22.113

6.  Detection and distribution of aluminium in bone.

Authors:  J Denton; A J Freemont; J Ball
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

7.  Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept.

Authors:  Patrick Garnero; Nadine Charni-Ben Tabassi; Nathalie Voorzanger-Rousselot
Journal:  J Rheumatol       Date:  2008-10-01       Impact factor: 4.666

8.  Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.

Authors:  Aníbal Ferreira; João Miguel Frazão; Marie-Claude Monier-Faugere; Célia Gil; José Galvao; Carlos Oliveira; Jorge Baldaia; Ilidio Rodrigues; Carla Santos; Silvia Ribeiro; Regula Mueller Hoenger; Ajay Duggal; Hartmut H Malluche
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

9.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

10.  Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

Authors:  Mariateresa Fulciniti; Pierfrancesco Tassone; Teru Hideshima; Sonia Vallet; Puru Nanjappa; Seth A Ettenberg; Zhenxin Shen; Nipun Patel; Yu-Tzu Tai; Dharminder Chauhan; Constantine Mitsiades; Rao Prabhala; Noopur Raje; Kenneth C Anderson; David R Stover; Nikhil C Munshi
Journal:  Blood       Date:  2009-05-05       Impact factor: 22.113

View more
  71 in total

1.  Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study.

Authors:  Min Li; Hua Zhou; Min Yang; Changying Xing
Journal:  Int Urol Nephrol       Date:  2018-12-04       Impact factor: 2.370

2.  Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.

Authors:  Y Asamiya; A Yajima; S Shimizu; S Otsubo; K Tsuchiya; K Nitta
Journal:  Osteoporos Int       Date:  2014-11-04       Impact factor: 4.507

Review 3.  Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities.

Authors:  Takashi Hirukawa; Takatoshi Kakuta; Michio Nakamura; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2015-05-02       Impact factor: 2.801

Review 4.  Renale osteodystrophie.

Authors:  Daniel Cejka
Journal:  Wien Med Wochenschr       Date:  2013-05-09

5.  The relation between renal function and serum sclerostin in adult patients with CKD.

Authors:  Solenne Pelletier; Laurence Dubourg; Marie-Christine Carlier; Aoumeur Hadj-Aissa; Denis Fouque
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 8.237

Review 6.  Biomarkers Predicting Bone Turnover in the Setting of CKD.

Authors:  Pieter Evenepoel; Etienne Cavalier; Patrick C D'Haese
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

7.  Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.

Authors:  Daniel Cejka; Diego Parada-Rodriguez; Stefanie Pichler; Rodrig Marculescu; Ina Kramer; Michaela Kneissel; Thomas Gross; Andreas Reisinger; Dieter Pahr; Marie-Claude Monier-Faugere; Martin Haas; Hartmut H Malluche
Journal:  Kidney Int       Date:  2016-08-12       Impact factor: 10.612

Review 8.  Updates in CKD-Associated Osteoporosis.

Authors:  Pascale Khairallah; Thomas L Nickolas
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 9.  Bone kidney interactions.

Authors:  Thomas L Nickolas; Sophie A Jamal
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

10.  Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.

Authors:  Wei Lv; Lina Guan; Yan Zhang; Shengqiang Yu; Bofeng Cao; Yongqiang Ji
Journal:  Int Urol Nephrol       Date:  2016-07-27       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.